Caricamento...
Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
Lorlatinib treatment should be positively considered even for patients with ALK‐positive NSCLC with severe neurocognitive disturbance and poor performance status due to CNS metastases, including leptomeningeal carcinomatosis.
Salvato in:
| Pubblicato in: | Clin Case Rep |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8077276/ https://ncbi.nlm.nih.gov/pubmed/33936630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3927 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|